Are there any studies that specify what level of antibodies is protective and what level is an indication to offer a booster?
Dear Dr Monika Klimek-Tulwin . See the following useful RG link: Article A Systematic Review of the Protective Effect of Prior SARS-C...
Kindly see also the following useful RG link: Article Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SAR...
Also check please the following useful RG link: Article Correlation between a quantitative anti‐SARS‐CoV‐2 IgG ELISA...
The following RG link is also very useful: Article Evidence for antibody as a protective correlate for COVID-19 vaccines
Please, see the following helpful link:
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00307-4/fulltext
Dear Monika Klimek-Tulwin it was estimated that an antibody level of 100 AU/ml is the minimum level for protection against the virus,
In clinical practice, the antibody levels are not done before deciding whether a person should get a 2-dose series of COVID-19 vaccination without or with a prior SARS-CoV-2 documented infection.
This is because of the expense of testing SARS-CoV-2 antibody titers, different antibody test kits available, and the availability of these tests in reference or research laboratories.
The cutoff values of neutralizing antibody titers differ whether the antibody test is done to check protection after a confirmed SARS-CoV-2 infection (based on a positive RT-PCR test) or protection after a vaccination series.
1. After a documented SARS-CoV-2 infection, when the neutralizing antibody titers were done, the cutoff anti-RBD antibodies was ≥250 U/tmLr or over (1). In a meta-analysis of protection from reinfection after prior documented COVID-19 was considered without doing the titers of protective antibodies (2)
2. In studies of protective antibodies after COVID-19 vaccinations, the degree of protection from SARS-CoV-2 breakthrough infection 2 weeks after vaccination series. Vaccine recipients with postvaccination 50% neutralization titers (IU/mL) of 10, 100, and 1000 had estimated vaccine efficacies of 78%, 91%, and 96%, respectively.
1. Article Prevalence and Durability of SARS-CoV-2 Antibodies Among Unv...
2. Article A Systematic Review of the Protective Effect of Prior SARS-C...
3. Article Immune correlates analysis of the mRNA-1273 COVID-19 vaccine...
- Badges
- Science topic
- Similar topics
- Biological Science
- Immunology
- Antibodies